Palforzia is the first FDA approved drug to be used for peanut OIT
Peanut allergy, an increasingly prevalent health condition, has previously been managed by strict avoidance and appropriate treatment of any accidental exposures. Studies estimate the risk of accidental exposure to be somewhere between 10- 15% per year, with adolescents and those newly diagnosed representing a high-risk group. Inadvertent exposure may occur through inadequate labelling, ‘hidden’ sources, inadequately cleaned utensils and surfaces, and more rarely just through contact with someone who has eaten peanuts.
Oral immunotherapy (OIT) has altered the face of peanut allergy management. Although OIT cannot ‘cure’ the allergy, tolerance to peanuts is created by ingesting increasing amounts of peanut protein. This process must be highly supervised and is based on a protocol that starts with extremely small doses of peanut protein which are increased gradually. When tolerance to higher doses is achieved, accidental exposures are then less likely to produce reactions. Palforzia is the first FDA approved drug to be used for peanut OIT. Read all about it at the following the links below.